Vasoconstriction to Endogenous Endothelin-1 Is Increased in the Peripheral Circulation of Patients With Essential Hypertension

Stefano Taddei, MD; Agostino Virdis, MD; Lorenzo Ghiadoni, MD; Isabella Sudano, MD; Massimo Notari, MD; Antonio Salvetti, MD

Background—In humans, endothelin (ET)-1 could be implicated in the pathophysiology of several cardiovascular diseases, including essential hypertension. We therefore evaluated the role of ET-1 in control of vascular tone in essential hypertension.

Methods and Results—We used strain-gauge venous plethysmography to test changes in forearm blood flow induced by intrabrachial infusion of TAK-044 (10, 30, and 100 μg · 100 mL⁻¹ · min⁻¹), an ETₐ/ETₐ receptor antagonist, or sodium nitroprusside (1 and 2 μg · 100 mL⁻¹ · min⁻¹), a vasodilator that acts on smooth muscle cells, in hypertensive patients and healthy controls (n=10 in each group). The NO pathway was also evaluated by infusion of N⁶-monomethyl-L-arginine, (L-NMMA; 10, 30, and 100 μg · 100 mL⁻¹ · min⁻¹), an NO synthase inhibitor, and norepinephrine (3, 9, and 30 ng · 100 mL⁻¹ · min⁻¹) as control. Immunoreactive plasma ET-1 was measured by radioimmunoassay. In hypertensive patients, TAK-044 caused a vasodilatation that was significantly (P<0.01) increased compared with normotensive subjects. Moreover, vasoconstriction to L-NMMA was significantly (P<0.01) decreased in hypertensive patients compared with controls. In contrast, the vascular responses to sodium nitroprusside and norepinephrine, as well as levels of immunoreactive plasma ET-1, were similar in hypertensive patients and controls. In the study population, vasodilatation to TAK-044 and vasoconstriction to L-NMMA showed an inverse correlation (r=−0.56, P<0.05).

Conclusions—These results indicate that TAK-044 caused a greater degree of vasodilation in the forearm vessels of essential hypertensive patients compared with normotensive subjects, an alteration associated with decreased tonic NO release. (Circulation. 1999;100:1680-1683.)

Key Words: vasodilation ■ hypertension ■ nitric oxide ■ endothelin

Endothelin-1 (ET-1), a 21-amino-acid isopeptide generated by the vascular endothelium and characterized by sustained and potent vasoconstrictor action, acts through specific receptors termed ETₐ and ETₐ. ETₐ receptors are located both on smooth muscle cells and mediate contractions and promote growth. In contrast, ETₐ receptors are activated by the vascular endothelium and characterized by no history of smoking or drinking and by similar values of plasma glucose, total and LDL cholesterol, and creatinine clearance (all within normal ranges). The protocol was approved by the ethics committee of the University of Pisa, and all patients gave written consent to participate in the study.

In the present study, we compared forearm vasodilatation to TAK-044, a combined ETₐ/ETₐ receptor antagonist, in healthy control subjects and patients with essential hypertension to indirectly assess the contribution of endogenous ET-1 to vascular tone in both conditions. Moreover, the activity of the L-arginine–NO pathway was also evaluated.

Methods

The study population included 10 normotensive control subjects (age 51.2±6.4 years; blood pressure 121.4±4.3/78.2±3.2 mm Hg) and 10 matched never-treated patients with essential hypertension (age 50.6±6.8 years; blood pressure 160.2±6.2/101.6±2.8 mm Hg) characterized by no history of smoking or drinking and by similar values of plasma glucose, total and LDL cholesterol, and creatinine clearance (all within normal ranges). The protocol was approved by the ethics committee of the University of Pisa, and all patients gave written consent to participate in the study.
Briefly, the brachial artery was cannulated for drug infusion at systematically ineffective rates and for monitoring of intra-arterial blood pressure and heart rate. Forearm blood flow (FBF) was measured in both forearms by strain-gauge venous plethysmography. Circulation to the hand was excluded 1 minute before FBF measurement.

<table>
<thead>
<tr>
<th>Hemodynamic Parameters During Infusion of TAK-044, SNP, L-NMMA, and NE</th>
<th>Normotensive Subjects</th>
<th>Essential Hypertensive Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>MBP, mm Hg</td>
<td>HR, bpm</td>
<td>FVR ex, U</td>
</tr>
<tr>
<td>TAK-044</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>90.5±4.2</td>
<td>73.0±3.9</td>
</tr>
<tr>
<td>10 µg · 100 mL⁻¹ · min⁻¹</td>
<td>90.5±4.3</td>
<td>72.8±4.4</td>
</tr>
<tr>
<td>30 µg · 100 mL⁻¹ · min⁻¹</td>
<td>90.0±4.3</td>
<td>72.6±4.2</td>
</tr>
<tr>
<td>100 µg · 100 mL⁻¹ · min⁻¹</td>
<td>90.0±4.6</td>
<td>72.5±4.0</td>
</tr>
<tr>
<td>SNP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>90.4±4.2</td>
<td>72.4±4.6</td>
</tr>
<tr>
<td>1 µg · 100 mL⁻¹ · min⁻¹</td>
<td>90.5±4.3</td>
<td>72.2±4.6</td>
</tr>
<tr>
<td>2 µg · 100 mL⁻¹ · min⁻¹</td>
<td>90.5±4.3</td>
<td>72.6±4.4</td>
</tr>
<tr>
<td>L-NMMA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>89.8±4.5</td>
<td>72.9±3.5</td>
</tr>
<tr>
<td>10 µg · 100 mL⁻¹ · min⁻¹</td>
<td>89.8±4.5</td>
<td>72.7±3.8</td>
</tr>
<tr>
<td>30 µg · 100 mL⁻¹ · min⁻¹</td>
<td>89.9±4.4</td>
<td>72.9±3.7</td>
</tr>
<tr>
<td>100 µg · 100 mL⁻¹ · min⁻¹</td>
<td>90.0±4.5</td>
<td>71.7±4.2</td>
</tr>
<tr>
<td>NE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>89.9±4.7</td>
<td>72.4±4.3</td>
</tr>
<tr>
<td>3 ng · 100 mL⁻¹ · min⁻¹</td>
<td>89.8±4.5</td>
<td>72.5±4.1</td>
</tr>
<tr>
<td>9 ng · 100 mL⁻¹ · min⁻¹</td>
<td>89.9±4.7</td>
<td>72.9±4.0</td>
</tr>
<tr>
<td>30 ng · 100 mL⁻¹ · min⁻¹</td>
<td>90.0±4.8</td>
<td>72.7±4.2</td>
</tr>
</tbody>
</table>

Ex indicates experimental; c, contralateral. *P<0.01 or †P<0.001 vs baseline.

Results

The Table describes mean blood pressure, heart rate, and experimental and contralateral FVR behavior during each infusion.

In healthy subjects, TAK-044 caused a modest increase in FBF (Figure 1) and a decrease in FVR (−12.3±17.2%), whereas in patients with essential hypertension, the FBF increase (Figure 1) and FVR decrease (−47.2±12.1%) were significantly (P<0.01) greater than for normotensive controls. L-NMMA caused a decrease in FBF (Figure 1), which was significantly (P<0.01) reduced in essential hypertensive patients (FVR increase 41.4±14%) compared with normotensive subjects (FVR increase 95.3±41%). Vasodilation to SNP and vasoconstriction to NE were similar in normotensive subjects and hypertensive patients. Contralateral FVR did not significantly change throughout the study (Table).

With regard to the entire study population, vasodilation to TAK-044 was negatively (r=−0.56, P<0.05) correlated with vasoconstriction to L-NMMA (Figure 2). Plasma immunoreactive ET was similar in normotensive subjects (4.9±0.1 pg/mL) and hypertensive patients (4.3±0.1 mg/mL).

Discussion

The present results show that TAK-044, a combined ETₐ/ET₇ receptor antagonist, caused a greater degree of vasodilation in the forearm vasculature of patients with essential hypertension than in normotensive control subjects, whereas the response to SNP, a direct relaxant compound, was similar in...
sucrose-based controls and essential hypertensives with normal renal ET-1 concentrations were found to be similar in normoten-

function. However, because only ∼20% of generated ET is secreted luminally, whereas the greater portion of the peptide is secreted toward the adjacent smooth muscle,15 plasma ET measurement is not a sensitive marker for tissue production of the peptide. In line with this possibility and in agreement with previous evidence,17 our hypertensive study population was characterized by an impairment in the NO system, because the vasoconstrictor effect of L-NMMA but not that of the unrelated vasoconstrictor NE was decreased compared with healthy controls. Moreover, the existence of a negative and significant correlation between the vasodilating and vasoconstricting responses to TAK-044 and L-NMMA, respectively, seems to indicate an association between increased vasoconstriction to endogenous ET-1 and diminished NO production. Finally, recent evidence indicates that intrabrachial infusion of BQ-788, a selective ETB receptor antagonist, causes vasodilation and vasoconstriction in essential hypertensives and normotensive controls, respectively,18 further supporting the existence of a differential vascular activity for ETB receptors in healthy conditions and in patients with essential hypertension.

In conclusion, in essential hypertension, the vasoconstric-
tor activity of endogenous ET-1 is increased compared with healthy conditions, which suggests a possible role for ET-1 in the pathogenesis of hypertension and/or its complications.

References

**References**


Vasoconstriction to Endogenous Endothelin-1 Is Increased in the Peripheral Circulation of Patients With Essential Hypertension

Stefano Taddei, Agostino Virdis, Lorenzo Ghiadoni, Isabella Sudano, Massimo Notari and Antonio Salvetti

Circulation. 1999;100:1680-1683
doi: 10.1161/01.CIR.100.16.1680

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/100/16/1680

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/